Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of p...

Full description

Bibliographic Details
Main Authors: Carlo Capalbo, Giorgia Scafetta, Marco Filetti, Paolo Marchetti, Armando Bartolazzi
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:International Journal of Molecular Sciences
Subjects:
galectin-3
non-small cell lung carcinoma
pembrolizumab
checkpoint inhibitors
predictive marker
Online Access:https://www.mdpi.com/1422-0067/20/7/1607

Internet

https://www.mdpi.com/1422-0067/20/7/1607

Similar Items